A stock market shakes low in the morning. The main index is generally declined. The Shanghai Index fell more than 1%, the GEM index fell nearly 2%. The A -stock market fell more than 4,200 shares.
closed in the morning, the Shanghai Stock Exchange Index fell more than 1%, fallen 1.1%, the Shenzhen Stock Exchange Index fell 1.95%, the GEM index fell 1.95%, the science and technology 50 index fell 2.4%, the individual stocks fell 4273, 462 rose, the transaction transaction rose, the transaction transaction rose, the transaction transaction rose, and the transaction rose. Under 599.7 billion yuan. The
car sector rises against the trend. Zhongtong Bus 8 -consecutive board
car sector rises against the trend. Matsunhara's "20 cm" daily limit. It is worth noting that this is Zhongtong Bus 8 consecutive board, and the stock price has doubled.
Recently, according to the "Shandong News Broadcast" report, the nucleic acid detection vehicle independently developed by Zhongtong Bus, with the advantages of flexible, complete facilities, high -efficiency detection, and rapid deployment, to create a number of leading technologies, the "mobile party, the mobile party The cabin ", in many places in the country, showed the deep strength of Qi Luzhi. After
BYD's stock price rose continuously a few days ago, it fell this morning, and the market fell more than 3%.
According to the official WeChat public account of the "China Automobile Association Data", the statistical analysis of the China Automobile Industry Association, from January to April 2022, the top ten companies (groups) of automobile sales were 6.594 million vehicles, accounting for total automobile sales. 85.7%of the amount. Among the top ten companies in automobile sales, compared with the same period last year, BYD's sales growth rate is still the most obvious. GAC and Chery have a slightly lower growth rate, and other companies have declined.
New Crossing Pills has made progress.
. 100 billion white horse stocks have plummeted
today's A -share market. The most surprising thing is the killing of Junshi creatures. The stock fell more than 16%in the early days. However, the opening of A shares rose nearly 2%, and the opening of H shares rose nearly 5%.
In fact, last night, Junshi creatures were beneficial to happen. Junshi Biological announced on the evening of May 23 that its holding subsidiary Jun Tuo Biology and Wangshan Wangshui cooperated with the product oral nucleoside anti-SARSCOV-2 drug VV116 tablets ("VV116") The Weitian/Litonavid (ie PaxLovid) used for the main end point of the preset plan for the early treatment of the III registered clinical research (NCT05341609) for the early treatment of a light medium-sized new coronary virus pneumonia ("COVID-19"). The company will recently communicate with the regulatory department to submit a new drug listing application.
has professionals who believe that this time it only announced the main end point, and complete data will be released more formally on subsequent appropriate occasions. At present, the data is fully supported, and the company will recently communicate with the drug supervision department to submit the application of new drug listing.
's endpoint indicator will be seen again in the complete data. However, the company's main end point, that is, "continuous clinical recovery" refers to all COVID-19 related target symptom scores = 0 points for 2 consecutive days. (The percentage of the percentage defined as a progressive/critical COVID-19 or all due to death "is unlikely to be unlikely. Under the careful assumptions of
, it is expected to be priced at 500 yuan/person in China. The first year of sales of 20 million treatment courses, sales exceeded 10 billion, and sold for 40 million treatment for the second year. This has not taken into account the government's procurement and preparation of stocks and overseas markets. "Actually far exceeds our assumptions," said the professionals. In terms of
, the major progress of the new crown oral medication is favorable for the company itself and the entire market. So, why is the benefits of Junshi creatures become sharp? Some market participants believe that the clinical trials of Junshi creatures may have flaws.
Private Equity Big Drom Danbin: At present, about 10%of light positions,
plus positions participating in rebounding
, in addition, Dan Bin, who has received much attention because of low warehouses, has recently spoken again. According to the Financial Association, Bin talked about market views and positions in the roadshow recently.
Dan Bin said that this year's operation has now escaped the market plunge in two, three, and four months.Now maintaining a 10%position, it is a crisis in the market that is mainly based on the liquid liquor. At present, the company's management scale is about 25 billion, and the purchase and redemption have not changed much.
Dan Bin said that about 10%of the positions are equivalent to a very light position. After 2008, 2015, including 2018, from the beginning of the year to the end of the year, it seems very lively in the middle, and it is still difficult to rebound.
Dan Bin said, of course, you can do it in the bear market or in the weakness. When I personally prepare to find another suitable point next time, we will also participate in the rebound in the disadvantaged. We will participate in the phased rebound at a small position or 20%or 30%of positions.
Dan Bin believes that in general, big opportunities may have to wait until the third or fourth quarter.
